A dose escalation phase 1 study of radiotherapy (RT) in combination with anti-cytotoxic-T-lymphocyte-associated antigen 4 (CTLA-4) monoclonal antibody ipilimumab in patients (pts) with metastatic melanoma.

Céline Boutros,C. Mateus,Emilie Lanoy,E. Routier,Salem Chouaib,Dominique Schwob,Stéphan Vagner,Isabelle Girault,Caroline Caramella,Salima Hibat,yun Gan Tao,Kim Cao,Nathalie Chaput,Julien Adam,Jean-Charles Soria,Alexander Eggermont,Eric Deutsch,Caroline Robert

A dose escalation phase 1 study of radiotherapy (RT) in combination with anti-cytotoxic-T-lymphocyte-associated antigen 4 (CTLA-4) monoclonal antibody ipilimumab in patients (pts) with metastatic melanoma.

2017

Céline Boutros
C. Mateus
Emilie Lanoy
E. Routier
Salem Chouaib
Dominique Schwob
Stéphan Vagner
Isabelle Girault
Caroline Caramella
Salima Hibat
yun Gan Tao
Kim Cao
Nathalie Chaput
Julien Adam
Jean-Charles Soria
Alexander Eggermont
Eric Deutsch
Caroline Robert

9549Background: Preclinical findings have shown a synergy between RT and anti-CTLA-4 monoclonal antibody in several tumor animal models for both local tumor control and distant effects. Preliminary...

Keywords:

Cytotoxic T-Lymphocyte-Associated Antigen 4
Melanoma
Ipilimumab
Cancer research
Pathology
Radiation therapy
Monoclonal antibody
CTLA-4
Medicine
metastatic melanoma
in patient
dose escalation

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations